Belinostat (PXD101, NSC726630, PX-105684, PXD-101, NSC-726630, PX105684)，又称贝利司他，是羟肟酸型HDAC抑制剂，IC₅₀值为27 nM，在癌细胞中能增加组蛋白H3和H4的乙酰化，表现出细胞毒性效应，有抗癌功效，可用于治疗复发性或难治性外周T细胞淋巴瘤。

参考文献

[1] Plumb JA, et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther. 2003 Aug;2(8):721-8.

[2] V M Richon, et al. A Class of Hybrid Polar Inducers of Transformed Cell Differentiation Inhibits Histone Deacetylases.Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3003-7.

[3] Chowdhury S, et al. Histone deacetylase inhibitor belinostat represses survivin expression through reactivation of transforming growth factor beta (TGFbeta) receptor II leading to cancer cell death. J Biol Chem. 2011 Sep 2;286(35):30937-30948.

冰袋运输。粉末直接保存于-20℃，有效期3年。建议分装后-20℃干燥保存，避免反复冻融。